Evidence map›Paper›PMID 42782508›Full record

ArticleDiabetologia2026

Sphinganine as a novel stimulator of GLP-1 secretion.

Mark M Smits, Anna K Drzazga, Jarkko J Lackman, Maria Akhlef, Samuel A J Trammell, Astrid M Baattrup, Ole H Nielsen, Kim B Jensen, Viktor Gerdes, Arnold van de Laar and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mark M SmitsDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. mark.smits@radboudumc.nl.
Anna K DrzazgaDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Jarkko J LackmanDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Maria AkhlefDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Samuel A J TrammellDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Astrid M BaattrupDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Ole H NielsenDepartment of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
Kim B JensenDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Viktor GerdesDepartment of Internal Medicine, Amsterdam University Medical Center, location AMC, Amsterdam, the Netherlands.
Arnold van de LaarDepartment of Surgery, Spaarne Gasthuis, Hoofddorp, the Netherlands.
Sjoerd BruinDepartment of Surgery, Spaarne Gasthuis, Hoofddorp, the Netherlands.
Trisha J GrevengoedDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Mette M RosenkildeDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Jens J HolstDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Funding

Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers ACS Postdoc grantEuropean Foundation for the Study of Diabetes EFSD/Lilly Young Investigator Research Award ProgrLundbeck Foundation Postdoc fellowshipNovo Nordisk Fonden NNF21CC0073729Novo Nordisk Fonden NNF23CC0084611
6 · The paper itself

Abstract

aims/hypothesisMechanisms of secretion of the gut hormone glucagon-like peptide-1 (GLP-1) remain incompletely understood yet are relevant for the pathophysiology and treatment of obesity and diabetes. Here, we set out to identify novel triggers.

methodsWe started with using metabolomics on plasma samples from meal tests in adults, where we identified sphinganine, a sphingolipid, as the strongest predictor of a high GLP-1 response. Sphinganine was next tested in vitro (in GLUTag and NCI-H716 cell lines and human intestinal organoids), ex vivo (in isolated rat intestinal and colon perfusion models) and in vivo (using both single acute administration and prolonged feeding in mice).

resultsSphinganine doubled GLP-1 secretion in vitro in multiple cell lines and human intestinal organoids, via G-protein-coupled receptor 40-mediated mechanisms. In isolated intestinal perfusion model in rats, sphinganine increased GLP-1 during luminal administration. However, this effect was only statistically significant in male rats. In vivo, oral administration of sphinganine to mice did not increase GLP-1 acutely or after prolonged feeding. In the prolonged-feeding model, however, it did reduce high-fat-diet-induced weight gain, without changing food intake. CONCLUSIONS/

interpretationOur data indicate beneficial metabolic effects of sphingolipids and points towards potential therapeutic effects to be explored.

Indexed as

DiabetesGLP-1Glucagon-like peptideObesityPerfusion studiesSphinganineSphingolipids

Identifiers

PMID42782508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.